MCID: DRG016
MIFTS: 24

Drug Induced Dyskinesia

Categories: Rare diseases

Aliases & Classifications for Drug Induced Dyskinesia

MalaCards integrated aliases for Drug Induced Dyskinesia:

Name: Drug Induced Dyskinesia 53
Dyskinesia, Drug Induced 53
Dyskinesia, Drug-Induced 72
Drug-Induced Dyskinesia 17

Classifications:



External Ids:

UMLS 72 C0013386

Summaries for Drug Induced Dyskinesia

NIH Rare Diseases : 53 Drug induced dyskinesia is an involuntary movement disorder. Signs and symptoms include repetitive and irregular motions of the mouth, face, limbs and/or trunk. Treatment with antipsychotic drugs and levodopa (commonly used to treat Parkinson disease) are well recognized causes of drug-induced dyskinesia. Dyskinesia develops in around 40% of people with Parkinson's disease who have been on levodopa treatment for four to six years. Tardive dyskinesia is a severe form of drug-induced dyskinesia due to antipsychotic treatments. Tardive dyskinesia develops in 5% of people per year of treatment.

MalaCards based summary : Drug Induced Dyskinesia, also known as dyskinesia, drug induced, is related to tardive dyskinesia and chorea, childhood-onset, with psychomotor retardation, and has symptoms including ataxia, tremor and myoclonus. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, subthalamic nucleus and cortex.

Related Diseases for Drug Induced Dyskinesia

Diseases related to Drug Induced Dyskinesia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 16)
# Related Disease Score Top Affiliating Genes
1 tardive dyskinesia 10.2
2 chorea, childhood-onset, with psychomotor retardation 10.2
3 choreatic disease 10.2
4 dystonia 10.2
5 huntington disease 9.9
6 parkinson disease, late-onset 9.9
7 torticollis 9.9
8 neuronal intranuclear inclusion disease 9.9
9 focal dystonia 9.9
10 tic disorder 9.9
11 movement disease 9.9
12 speech disorder 9.9
13 pathologic nystagmus 9.9
14 athetosis 9.9
15 dysphagia 9.9
16 tremor 9.9

Graphical network of the top 20 diseases related to Drug Induced Dyskinesia:



Diseases related to Drug Induced Dyskinesia

Symptoms & Phenotypes for Drug Induced Dyskinesia

UMLS symptoms related to Drug Induced Dyskinesia:


ataxia, tremor, myoclonus, dystonia, athetosis, synkinesis

Drugs & Therapeutics for Drug Induced Dyskinesia

Drugs for Drug Induced Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Amantadine Approved Phase 4 768-94-5 2130
4
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
5 Serotonin Receptor Agonists Phase 4
6 Serotonin 5-HT2 Receptor Antagonists Phase 4
7 Serotonin 5-HT1 Receptor Agonists Phase 4
8 Dopamine D2 Receptor Antagonists Phase 4
9 Dopamine Agents Phase 4
10 Neurotransmitter Agents Phase 4
11 Antiparkinson Agents Phase 4
12 Psychotropic Drugs Phase 4
13 Antidepressive Agents Phase 4
14 Dopamine agonists Phase 4
15 Peripheral Nervous System Agents Phase 4
16 Autonomic Agents Phase 4
17 Analgesics Phase 4
18 Analgesics, Non-Narcotic Phase 4
19 Anti-Infective Agents Phase 4
20 Antiviral Agents Phase 4
21 Cardiotonic Agents Phase 4
22 Sympathomimetics Phase 4
23 Neuroprotective Agents Phase 4
24 Monoamine Oxidase Inhibitors Phase 4
25 Protective Agents Phase 4
26
Levodopa Approved Phase 3 59-92-7 6047
27
Levetiracetam Approved, Investigational Phase 2 102767-28-2 441341
28
Topiramate Approved Phase 2 97240-79-4 5284627
29 Dihydroxyphenylalanine Phase 2
30 Nootropic Agents Phase 2
31 Tranquilizing Agents Phase 2
32 Central Nervous System Depressants Phase 2
33 Antipsychotic Agents Phase 2
34 Anticonvulsants Phase 2
35 Hypoglycemic Agents Phase 2
36
Olanzapine Approved, Investigational Phase 1 132539-06-1 4585
37
Risperidone Approved, Investigational Phase 1 106266-06-2 5073
38 Serotonin Antagonists Phase 1
39 Serotonin Agents Phase 1
40 Dopamine Antagonists Phase 1
41 Serotonin Uptake Inhibitors Phase 1
42 Gastrointestinal Agents Phase 1
43 Quetiapine Fumarate Phase 1 111974-72-2
44 Antiemetics Phase 1
45 Neurotransmitter Uptake Inhibitors Phase 1
46
Serotonin Investigational, Nutraceutical Phase 1 50-67-9 5202
47
Simvastatin Approved 79902-63-9 54454
48
Lovastatin Approved, Investigational 75330-75-5 53232
49
Acetylcholine Approved, Investigational 51-84-3 187
50 Lipid Regulating Agents

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study Unknown status NCT00837707 Phase 4 aripiprazole
2 The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
3 Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications Completed NCT00443872 Phase 4 orally disintegrating selegiline (Zelapar)
4 Therapeutic Use of Piracetam for Treatment of Patients Suffering From Tardive Dyskinesia: a Double Blind, Placebo-Controlled Crossover Study Completed NCT00190008 Phase 3 piracetam
5 A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations Not yet recruiting NCT03987750 Phase 3 Safinamide Methanesulfonate 150mg;Safinamide Methanesulfonate 100mg;Safinamide Methanesulfonate matching placebo
6 An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias Completed NCT01173731 Phase 2 AFQ056
7 An 8-week Exploratory, Double-blind, Placebo Controlled, Randomized Trial: Evaluation of the Efficacy and Safety of Levetiracetam up to 3000 mg/Day (250-500 mg Oral Tablets in b.i.d. Administration) on Neuroleptic-induced Tardive Dyskinesia in Subjects With Stable Axis I Psychiatric Disorder, Aged From at Least 18 Years to 80 Years. Completed NCT00175955 Phase 2 Levetiracetam
8 A 6-week, Double-blind, Placebo-controlled, Randomized, Multicenter Study to Explore the Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With OFF Time and Moderate-severe L-dopa Induced Dyskinesia Completed NCT01092065 Phase 2 AFQ056 with L-dopa;Placebo
9 Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS) Completed NCT02657681 Phase 2
10 A Phase 2a, Multiple Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 in Reducing Anti Psychotic-Induced Extra Pyramidal Symptoms Among Subjects With Schizophrenia and Schizoaffective Disorders Terminated NCT00686699 Phase 2 Preladenant;Placebo
11 Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease Terminated NCT01789047 Phase 2 Topiramate;Placebo;Amantadine
12 Neuroleptic Induced Movement Disorders in Older Patients Completed NCT00255879 Phase 1 Quetiapine;Risperidone;Olanzapine
13 Targeting the Pre-supplementary Motor Area With Repetitive Transcranial Magnetic Stimulation to Alleviate Levodopa-induced Dyskinesia in Parkinson´s Disease Completed NCT03354455
14 STAT-PD: Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors Recruiting NCT04064294 Intravenous Infusion
15 A Training Protocol for the Use of Botulinum Toxin in the Treatment of Neurological Disorders Recruiting NCT00001208

Search NIH Clinical Center for Drug Induced Dyskinesia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


alpha-Tocopherol Acetate
Amantadine
Amantadine Hydrochloride
d-alpha-Tocopheryl Acetate
dl-alpha tocopheryl acetate
Tocopherol Acetate
TOCOPHEROL,DL-ALPHA
Tocopherols
TOCOPHERYL ACID SUCCINATE
TOCOPHERYL ACID SUCCINATE,D-ALPHA
Vitamin E

Genetic Tests for Drug Induced Dyskinesia

Anatomical Context for Drug Induced Dyskinesia

MalaCards organs/tissues related to Drug Induced Dyskinesia:

41
Brain, Subthalamic Nucleus, Cortex, Globus Pallidus

Publications for Drug Induced Dyskinesia

Articles related to Drug Induced Dyskinesia:

(show top 50) (show all 89)
# Title Authors PMID Year
1
Human Depotentiation following Induction of Spike Timing Dependent Plasticity. 38
29912149 2018
2
Cardinal Motor Features of Parkinson's Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia. 38
29843253 2018
3
Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment. 38
29304113 2018
4
D-512, a novel dopamine D2/3 receptor agonist, demonstrates greater anti-Parkinsonian efficacy than ropinirole in Parkinsonian rats. 38
28667675 2017
5
[Effects of bilateral deep brain stimulation in the subthalamic nucleus using two methods of target structure verification]. 38
29265083 2017
6
[Unilateral posteroventral pallidotomy in the treatment of drug-induced dyskinesia in Parkinson's disease]. 38
29076470 2017
7
Benefits of subthalamic stimulation for elderly parkinsonian patients aged 70 years or older. 38
27494146 2016
8
Orofacial Movement Disorders. 38
27475514 2016
9
Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. 38
27091214 2016
10
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. 38
27091215 2016
11
Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease. 38
26898686 2016
12
[The preliminary results of subthalamic nucleus stimulation after destructive surgery in Parkinson's disease]. 38
28139571 2016
13
Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia. 38
26363150 2015
14
One-year Outcome of Bilateral Subthalamic Stimulation in Parkinson Disease: An Eastern Experience. 38
26072454 2015
15
Bilateral subthalamic stimulation for advanced Parkinson disease: early experience at an Eastern center. 38
25394741 2015
16
Safinamide: first global approval. 38
25851099 2015
17
[Pain fluctuations in Parkinson's disease]. 38
26525814 2015
18
[Pharmacotherapy accompanied by deep brain stimulation of the subthalamic nucleus in patients with Parkinson's disease]. 38
28635789 2015
19
Effect of hydro-alcoholic root extract of Plumbago zeylanica l alone and its combination with aqueous leaf extract of Camellia sinensis on haloperidol induced parkinsonism in wistar rats. 38
25206060 2014
20
Deep brain stimulation improves survival in severe Parkinson's disease. 38
23843542 2014
21
Adaptive gene regulation in the Striatum of RGS9-deficient mice. 38
24663062 2014
22
Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia. 38
23632325 2013
23
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia? 38
23514355 2013
24
New insights into the mechanism of drug-induced dyskinesia. 38
23593652 2013
25
The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice. 38
22569849 2012
26
Comprehensive treatment of Huntington disease and other choreic disorders. 38
22761268 2012
27
Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease. 38
22093536 2011
28
Kinematic optimization of deep brain stimulation across multiple motor symptoms in Parkinson's disease. 38
21459111 2011
29
Context-driven changes in L-DOPA-induced behaviours in the 6-OHDA lesioned rat. 38
21220017 2011
30
Korean ginseng extract attenuates reserpine-induced orofacial dyskinesia and improves cognitive dysfunction in rats. 38
20628966 2011
31
Assessing drug-induced dyskinesia in the clinic, the laboratory and the natural environment of patients. 38
23939342 2011
32
Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. 38
20310033 2010
33
Neuronal intranuclear inclusion disease: two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia. 38
20629123 2010
34
A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease. 38
19726410 2010
35
Ziprasidone-related oculogyric crisis in an adult. 38
19717224 2009
36
The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. 38
18307261 2008
37
Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. 38
18417699 2008
38
Quantifying drug induced dyskinesia in Parkinson's disease patients using standardized videos. 38
19163023 2008
39
[Drug induced dyskinesia]. 38
17802711 2007
40
Deep brain stimulation in neurologic disorders. 38
17141550 2007
41
Bilateral subthalamotomy for advanced Parkinson disease. 38
17963922 2007
42
Modulation of human motor cortex excitability by single doses of amantadine. 38
16794570 2006
43
Parkinson's disease: diagnosis and treatment. 38
17186710 2006
44
Effect of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction. 38
16444668 2006
45
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. 38
15728856 2005
46
Unilateral stereotactic posteroventral globus pallidus internus pallidotomy for Parkinson's disease: surgical techniques and 2-year follow-up. 38
15754582 2005
47
The mechanism and effect of chronic electrical stimulation of the globus pallidus for treatment of Parkinson disease. 38
15200114 2004
48
Influence of age on iminodipropionitrile-induced vestibular and neurobehavioral toxicities in rats. 38
14620540 2003
49
Chronic metoclopramide therapy for diabetic gastroparesis. 38
12503946 2003
50
[Clinical and electromyographical analysis of peculiarities of parkinsonian syndrome in multiple system atrophy and Parkinson's disease]. 38
14681958 2003

Variations for Drug Induced Dyskinesia

Expression for Drug Induced Dyskinesia

Search GEO for disease gene expression data for Drug Induced Dyskinesia.

Pathways for Drug Induced Dyskinesia

GO Terms for Drug Induced Dyskinesia

Sources for Drug Induced Dyskinesia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....